Evidence map›Paper›PMID 34657192›Full record

ArticleDigestive diseases and sciences2022

Prevalence of Extensive and Limited Gastric Intestinal Metaplasia and Progression to Dysplasia and Gastric Cancer.

Monika Laszkowska, Han Truong, Adam S Faye, Judith Kim, Sarah Xinhui Tan, Francesca Lim, Julian A Abrams, Chin Hur

Open access · greenAbstract read
In one paragraph

Article in Digestive diseases and sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Guideline
  2. Observational
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Monika LaszkowskaDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA. LaszkowM@mskcc.org.ORCID 0000-0001-6816-3293
Han TruongDivision of General Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Adam S FayeDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Judith KimDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Sarah Xinhui TanDivision of General Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Francesca LimDivision of General Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Julian A AbramsDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Chin HurDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Columbia University Irving Medical Center · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
The Organoid and Cell Culture CoreP30DK132710 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Robert F. Schwabe · 2022 to 2026
$7.2M
Multidisciplinary Training in Translational Gastrointestinal and Liver ResearchT32DK083256 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Timothy Cragin Wang · 2009 to 2026
$5.5M
A Targeted Approach to the Surveillance of Precursor Lesions for Gastric CancerK08DK125876 · NIDDK · SLOAN-KETTERING INST CAN RESEARCH · PI LASZKOWSKA, MONIKA · 2021 to 2025
$838k
NCI NIH HHS P30 CA008748NIDDK NIH HHS K08 DK125876NIDDK NIH HHS P30 DK132710NIDDK NIH HHS T32 DK083256
6 · The paper itself

Abstract

BACKGROUND AND

aimsGuidelines cite extensive gastric intestinal metaplasia (GIM) as a bigger risk factor for gastric cancer (GC) than limited GIM and an indication for endoscopic surveillance. Data on progression of extensive GIM to GC in the USA are limited. This study aimed to estimate the prevalence and progression rates of extensive GIM in a US cohort.

methodsThis retrospective study assessed the prevalence of extensive GIM between 1/1/1990 and 8/1/2019 at a large academic medical center. Multivariable regression was used to identify predictors of extensive GIM. Incidence of GC on follow-up was calculated as number of new diagnoses divided by person-years of follow-up. Presence of GIM on subsequent follow-up endoscopy was assessed.

resultsOf 1256 individuals with GIM, 352 (28%) had extensive GIM and 904 (72%) had limited GIM. On multivariable analysis, older age (OR 1.01, 95% CI 1.00-1.02) and Hispanic ethnicity (OR 1.55, 95% CI 1.11-2.16) were predictive of extensive GIM. The annual incidence of GC for GIM overall was 0.09%. There was no difference in progression to GC between extensive or limited GIM (IRR 0, 95% CI 0-2.6), or to advanced lesions overall (IRR 0.37, 95% CI 0.04-1.62). 70% of individuals had persistent GIM on follow-up biopsy, and 22% with limited GIM had extensive GIM on follow-up biopsy.

conclusions28% of individuals with GIM have the extensive subtype, and are more likely to be older and of Hispanic ethnicity. There was no difference in progression to GC between extensive and limited GIM. Further research is needed to better assess risk of GIM in the US context.

Indexed as

Precancerous ConditionsStomach NeoplasmsEndoscopy, GastrointestinalHumansHyperplasiaMetaplasiaPrevalenceRetrospective StudiesGastric adenocarcinomaHigh grade dysplasiaIntestinal metaplasiaLow grade dysplasia

Identifiers

PMID34657192
PMCPMC9013391
OpenAlexW3207196352

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.